相似文献
1
Using Ticagrelor to Prevent Recurrent Type 1 and Type 2 Myocardial Infarctions: Boon or Bane?
J Am Heart Assoc. 2018 Nov 20;7(22):e010996. doi: 10.1161/JAHA.118.010996.
2
Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Thromb Haemost. 2014 Feb;111(2):266-72. doi: 10.1160/TH13-06-0508. Epub 2013 Oct 31.
3
Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Circulation. 2019 Apr 2;139(14):1661-1670. doi: 10.1161/CIRCULATIONAHA.118.038317.
4
Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y Receptor Inhibitors With and Without Aspirin: Results of the VORA-PRATIC Study.
J Am Heart Assoc. 2020 Apr 21;9(8):e015865. doi: 10.1161/JAHA.120.015865. Epub 2020 Apr 20.
5
Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
Circ Cardiovasc Interv. 2012 Dec;5(6):797-804. doi: 10.1161/CIRCINTERVENTIONS.112.972323. Epub 2012 Nov 20.
6
Features of antiplatelet therapy with P2Y12 receptor inhibitors in patients with myocardial infarction according to the Russian Register of Acute Myocardial Infarction REGION-MI.
Kardiologiia. 2022 Sep 30;62(9):44-53. doi: 10.18087/cardio.2022.9.n2278.
7
Infarct Size Following Treatment With Second- Versus Third-Generation P2Y12 Antagonists in Patients With Multivessel Coronary Disease at ST-Segment Elevation Myocardial Infarction in the CvLPRIT Study.
J Am Heart Assoc. 2016 May 31;5(6):e003403. doi: 10.1161/JAHA.116.003403.
8
Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation.
JACC Cardiovasc Interv. 2015 Sep;8(11):1457-1467. doi: 10.1016/j.jcin.2015.02.030.
9
Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction.
Arch Cardiovasc Dis. 2015 Oct;108(10):502-10. doi: 10.1016/j.acvd.2015.04.004. Epub 2015 Jun 22.
10
Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
Heart Vessels. 2020 Sep;35(9):1181-1192. doi: 10.1007/s00380-020-01598-w. Epub 2020 Apr 8.
本文引用的文献
1
Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54.
J Am Heart Assoc. 2018 Nov 20;7(22):e009260. doi: 10.1161/JAHA.118.009260.
2
Fourth Universal Definition of Myocardial Infarction (2018).
J Am Coll Cardiol. 2018 Oct 30;72(18):2231-2264. doi: 10.1016/j.jacc.2018.08.1038. Epub 2018 Aug 25.
3
Critical Appraisal of the 2018 ACC Scientific Sessions Late-Breaking Trials From a Statistician's Perspective.
J Am Coll Cardiol. 2018 Jun 26;71(25):2957-2969. doi: 10.1016/j.jacc.2018.04.015. Epub 2018 May 9.
4
Using Absolute Event Rates to See What Works in Cardiovascular Medicine.
J Am Coll Cardiol. 2017 Sep 12;70(11):1376-1378. doi: 10.1016/j.jacc.2017.07.764.
5
Bayesian Analysis: A Practical Approach to Interpret Clinical Trials and Create Clinical Practice Guidelines.
Circ Cardiovasc Qual Outcomes. 2017 Aug;10(8). doi: 10.1161/CIRCOUTCOMES.117.003563.
6
Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association.
Circulation. 2017 Mar 7;135(10):e146-e603. doi: 10.1161/CIR.0000000000000485. Epub 2017 Jan 25.
7
A Critical Appraisal of Aspirin in Secondary Prevention: Is Less More?
Circulation. 2016 Dec 6;134(23):1881-1906. doi: 10.1161/CIRCULATIONAHA.116.023952.
8
Long-term use of ticagrelor in patients with prior myocardial infarction.
N Engl J Med. 2015 May 7;372(19):1791-800. doi: 10.1056/NEJMoa1500857. Epub 2015 Mar 14.
9
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
Lancet. 2010 Nov 13;376(9753):1670-81. doi: 10.1016/S0140-6736(10)61350-5. Epub 2010 Nov 8.
10
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Lancet. 2009 May 30;373(9678):1849-60. doi: 10.1016/S0140-6736(09)60503-1.
Zotero 插件